AstraZeneca's FluMist nasal spray vaccine approved for self-administration
The U.S. FDA has given the green light for AstraZeneca's FluMist nasal spray vaccine to be self-administered or administered ...
AstraZeneca: Poised for Growth with Promising Innovation Pipeline and Attractive Valuation
In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on AstraZeneca (AZN – Research Report), with a ...
Daily2d
FDA approves Benralizumab for eosinophilic granulomatosis with polyangiitis
AstraZeneca's Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic ...
AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nod
Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...
AstraZeneca’s Fasenra meets primary endpoint in Phase III rare vasculitis trial
The Phase III trial compared the efficacy of Fasenra with the standard treatment of GSK’s Nucala in patients with ...
Pharmabiz3d
US FDA approves AstraZeneca’s Fasenra to treat eosinophilic granulomatosis with polyangiitis
AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated ...
MARKET REPORT: St Tropez maker burnt by Nigerian currency woes
The stock fell 15% after the consumer goods firm swung to a loss of £96m for the 12 months to the end of May, against a £62m ...
Managed Healthcare Executive3d
FDA Approves Fasenra for Treatment of Eosinophilic Granulomatosis with Polyangiitis
More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.
Medscape3d
FDA Approves Benralizumab for EGPA Vasculitis Indication
In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.
MedPage Today3d
FDA OKs New Option for Rare Immune-Mediated Vasculitis
EGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...
Yahoo Finance3d
AZN Oct 2024 100.000 call
WILMINGTON, Del., September 18, 2024--AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 ...